EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Bioleaders Corporation (142760) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Bioleaders Corporation KRW 687, price KRW 479, upside +43.4%, quality 27 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7142760008

BC Thin data Oct 3, 2026

Bioleaders Corporation

142760 · KQ

SpeculativeUpside exists, but weak quality makes the signal speculative.

Fair value 686.75 KRW · Undervalued (+43.4%)
Low debt
Mixed vs. peers (3/7)
Quality 27/100
Weak Growth (revenue 5y −32.6 %/yr in KRW)
Loss-making · -131.9% net margin (TTM)
Negative free cash flow
Narrow moat 12/100
Thin data
Watch Bioleaders Corporation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

17,400 KRW 374.00 KRW Fair Value 686.75 KRW Apr 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range 374.00 KRW – 17,400 KRW · fair‑value band 453.26 KRW – 858.44 KRW · the 479.00 KRW price screens below the 686.75 KRW fair value. Dashed = 300-day average. As of Oct 3, 2026.

Follow Bioleaders in your weekly email

Every Wednesday you see whether Bioleaders is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug.

Show more

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company's pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw materials, and cosmetics. The company was formerly known as Bioleaders Corporation and changed its name to MOA Life Plus Co. Ltd. in March 2024. MOA Life Plus Co. Ltd. was founded in 1999 and is headquartered in Yongin-Si, South Korea.

Stock analysis

Bioleaders Corporation (142760) currently trades at 479.00 KRW, while our model-based Fair Value estimate is 686.75 KRW, implying the stock looks roughly 30.3% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 453.26 KRW (bear) to 858.44 KRW (bull), the price of 479.00 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Bioleaders Corporation reported revenue of 11.2B KRW in FY2025 versus 101B KRW in FY2021, a compound −42.3%/yr. Reported net income was −13.1B KRW in FY2025.

Key figures

Market cap 18.7B KRW (≈ $13.9M) · P/S ratio 0.97 · Net margin −116% · Return on equity −48.8% · Return on assets (EBIT) −15.7% · Operating margin −208% · Revenue (TTM) 10.5B KRW · Revenue growth (YoY) +0.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 74% below its 52-week high and 28% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 43%, 142760 screens cheaper than that median.

Fair Value models

Bear 453.26 KRW Fair Value 686.75 KRW Bull 858.44 KRW
Price 479.00 KRW · Upside +43.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 724.86 KRW 971.31 KRW 1,450 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 724.86 KRW 971.31 KRW 1,450 KRW 54

Open the full fair value analysis →

Notify me when 142760 reaches fair value

Put 142760 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 27/100

Of which business quality 27 · Market factors (momentum, volatility) 21

Profitability 4
Margins and returns on capital today
Quality Growth 11
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 64
Balance sheet, leverage, solvency risk
Investment 80
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 11
Price trend over the last 3–12 months (market factor)
52W Momentum 4
Distance to the 52-week high (market factor)
Net Issuance 24
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−28.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−51.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−32.6%
Start year 2020 (pandemic). Over 10 years: +22.5% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−44.6% (2020) → −58.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 142760, get fair value alerts →

Compare Bioleaders Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 608 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside +43.4% · Top 25%
Profitability
Return on assets −17.4% · Below median
Net margin (TTM) −131.9% · Bottom 25%
Growth and dividend
Revenue growth 0.4% · Above median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)91 · sector 0
FUTURE (revenue growth)2 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $504.73 $555.20 +10%
Regeneron Pharmaceuticals, Inc REGN $735.20 $1,275 +73%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bioleaders Corporation · Fair Value
686.75 KRW +30%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Bioleaders Corporation Fair Value". https://www.fairvalue-calculator.com/stock/142760

Frequently asked questions

Is Bioleaders Corporation (142760) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 686.75 KRW versus a price of 479.00 KRW, about +43% upside (undervalued).
What is the fair value of 142760?
Our model-based fair value for Bioleaders Corporation is 686.75 KRW (as of Oct 3, 2026), built from audited fundamentals. The current price: 479.00 KRW.
What is the quality score of 142760?
Bioleaders Corporation has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bioleaders Corporation (142760)?
Our model-based price target is the fair value of 686.75 KRW (as of Oct 3, 2026) from 1 valuation models. Cautious scenario 453.26 KRW, optimistic scenario 858.44 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Bioleaders Corporation stock forecast for 2026?
Our models put fair value at 686.75 KRW, about +43% upside versus a price of 479.00 KRW (undervalued). Cautious scenario 453.26 KRW, optimistic scenario 858.44 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Bioleaders Corporation (142760)?
Bioleaders Corporation reported trailing-twelve-month revenue of about 10.5B KRW (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Bioleaders Corporation (142760)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bioleaders Corporation it is 686.75 KRW per share (as of Oct 3, 2026), against a price of 479.00 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Bioleaders Corporation stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 142760 trades below its calculated fair value: price 479.00 KRW, fair value 686.75 KRW, a gap of about +43% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 142760?
No. The price is what the market pays today (479.00 KRW); the fair value is what the company's own numbers justify (686.75 KRW). For Bioleaders Corporation the two are 207.75 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Bioleaders Corporation worth?
The market values Bioleaders Corporation at about 18.7B KRW (market capitalisation, as of Oct 3, 2026). Per share that is 479.00 KRW; our models calculate a fair value of 686.75 KRW per share.
What do the bullish and bearish scenarios say about 142760?
Our models span a range for Bioleaders Corporation: cautious scenario 453.26 KRW, base 686.75 KRW, optimistic 858.44 KRW per share (as of Oct 3, 2026, price 479.00 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Bioleaders Corporation (142760)?
Balance-sheet figures for Bioleaders Corporation (as of Oct 3, 2026): return on equity −48.8%. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is 142760 from its 52-week high?
Bioleaders Corporation trades at 479.00 KRW, about 74% below its 52-week high of 1,850 KRW and 28% above the low of 374.00 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 686.75 KRW is for.
Which stocks are comparable to Bioleaders Corporation?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bioleaders Corporation stock attractive at the current price?
The data as of Oct 3, 2026: price 479.00 KRW, calculated fair value 686.75 KRW (+43%), Quality Score 27/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 142760 calculated?
We run Bioleaders Corporation through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 686.75 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Bioleaders Corporation currently trades 30 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bioleaders Corporation (142760)?
The closing price on Oct 2, 2026 was 479.00 KRW. Our model-based fair value is 686.75 KRW, about +43% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bioleaders Corporation right now?
The large discount to fair value meets weak quality (27/100). That raises the risk this is a value trap rather than a bargain. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (453.26 KRW to 858.44 KRW) leaves room in how you read the outcome.

Key figures of Bioleaders Corporation

How large is the market capitalisation of Bioleaders Corporation (142760)?
The market capitalisation of Bioleaders Corporation is 18.7B KRW (≈ $13.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bioleaders Corporation (142760)?
The price-to-sales ratio of Bioleaders Corporation is 0.97 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Bioleaders Corporation (142760)?
The net margin of Bioleaders Corporation is −116% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bioleaders Corporation (142760)?
The return on equity (ROE) of Bioleaders Corporation is −48.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bioleaders Corporation (142760)?
On an EBIT basis the return on assets of Bioleaders Corporation is −15.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bioleaders Corporation (142760)?
The operating margin of Bioleaders Corporation is −208% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bioleaders Corporation (142760)?
Revenue at Bioleaders Corporation is growing +0.4% versus a year earlier (3y avg −51.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bioleaders Corporation (142760)?
Earnings per share at Bioleaders Corporation are growing −50.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Bioleaders Corporation (142760) generate?
The free cash flow of Bioleaders Corporation is −6.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Bioleaders Corporation (142760) carry?
The net debt of Bioleaders Corporation is 11.7B KRW (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Bioleaders Corporation in the live analysis

One click puts Bioleaders Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.